The KATHERINE trial evaluated the effectiveness of adjuvant T-DM1 in patients with HER2-positive breast cancer and residual disease after neoadjuvant chemotherapy with anti-HER2 therapy [35]. The gene discussed is ERBB2; the disease is breast cancer.